Genome-wide ZFX binding profiles in multiple types of human tumors. (A) ZFX ChIP-seq data for a region of ∼150 Mb of Chromosome X for HEK293T kidney, HCT116 colon, C4-2B prostate, and MCF-7 breast cancer cells (left) and for a region of ∼6 kb near the ZFX promoter (right). (B) The percentage of ZFX binding sites in promoters (±2 kb from the TSS), distal enhancers (H3K27ac), distal insulators (CTCF not in enhancers), and at other locations is shown for ZFX ChIP-seq data for four cell types. (C) The number of ZFX binding sites located in CpG island promoters versus non-CpG island promoters is shown for the four cell types. (D) Heatmap of the ChIP-seq signal correlation for ZFX binding sites in the four tumor types. (E) Venn diagrams of ZFX binding sites near promoters (left) and distal regions (right) for HEK293T kidney, HCT116 colon, C4-2B prostate, and MCF-7 breast cancer cells. (F) Examples of cell-type–specific and common ZFX binding sites.
